TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07095465: Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

Sponsor: ACADIA Pharmaceuticals Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 126 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,630,088

Rescue Site Savings

+$2,404,344

Unlock Full NCT07095465 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07095465 Rescue Dossier →